$A13.007 million cash supports 4.68 quarters of Archer development

Graphene Qubit Demonstration Remains the Main Technical Hurdle

Archer Materials Limited (ASX:AXE) is making commercial progress across its quantum and biosensor programs, but the milestone most closely tied to its core hardware ambition has slipped. The company said its functional graphene spin qubit demonstration is taking longer than anticipated because of technical challenges involved in developing a world-first device.

Archer stressed that it is continuing the program through parallel work streams and partner collaboration rather than rushing the milestone. Even a successful functional demonstration would be only an initial technical step, with further research, development and engineering required to establish whether the technology can become a scalable and commercially viable quantum chip. The company has continued wafer-scale fabrication and testing, while assessing additional graphene material suppliers and foundries.

IonQ Relationship Moves Towards Australian Customers

The quarter produced more tangible activity around Archer's quantum software and commercial strategy. Its strengthened relationship with IonQ included two days of planning with IonQ's leadership and technical teams, covering Australian customer pipeline development, quantum applications, algorithms, quantum communications and the early planning of potential onshore quantum computing capability.

The work builds on the IonQ sovereign computing deal, which previously gave Archer access to IonQ's quantum cloud services and opened discussions about deployment in Australia. Archer has now launched a National Quantum Commercial Pilot, inviting Australian enterprises to submit high-value computational problems for testing on IonQ hardware. Applications close on 15 November, with the stated aim of turning a selected group of problems into proof-of-concept projects with end users.

Fraud Detection Program Targets Q2 Benchmark Data

Archer's quantum machine learning collaboration with CSIRO remains targeted at quantified benchmark data by the middle of FY27. The next phase will test the fraud detection work on IonQ's Forte hardware, comparing quantum and classical approaches and building an evidence base for potential engagement with Australian financial institutions.

The company has also begun industry workshops, including a session with CSIRO aimed at financial services firms. Registrations have come from top-tier and mid-tier institutions, although the filing reports no customer contracts, revenue or completed proof-of-concept outcomes from the pilot.

Biochip Progresses Towards External Evaluation

On the diagnostics side, Archer completed several beta prototype iterations during the quarter, refining the cartridge, sensing architecture and readout electronics. The development follows the biosensor beta prototype, which had been positioned for manufacturability and external validation.

Archer said its Biochip is converging on a specification suitable for external evaluation by mid-FY27. It is planning an Australian testing pathway alongside discussions with a world-leading US clinical research institution, where the company is targeting a structured trial in the fourth quarter of FY27. Those plans remain targets rather than disclosed clinical results or binding commercial agreements.

Cash Runway Extends Across Multiple Programs

Archer finished the September quarter with $A13.007 million in cash, no debt and net operating cash usage of $A2.778 million. On the Appendix 4C calculation, that equates to an estimated 4.68 quarters of funding at the reported operating cash-flow rate. Net financing cash inflow was $A7.398 million, including $A7.501 million of equity issuance proceeds before transaction costs.

The balance gives Archer room to pursue its near-term milestones, but the company is advancing several technically demanding programs at once. The next evidence points are therefore unusually clear: Q2 benchmark data from the CSIRO collaboration, external Biochip testing, commercial pilot outcomes and a functional graphene qubit with readout. The timing of the last of those remains the least certain.